Vigil Neuroscience Appoints Samantha Budd Haeberlein, Ph.D. to Board of Directors
May 09 2023 - 7:00AM
Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage
biotechnology company committed to harnessing the power of
microglia for the treatment of neurodegenerative diseases, today
announced it appointed Samantha Budd Haeberlein, Ph.D. to its Board
of Directors.
“We are pleased to welcome Samantha Budd Haeberlein to our Board
of Directors. Samantha is a distinguished leader in the
pharmaceutical industry and brings extensive translational
medicine, clinical development and global regulatory experience in
the CNS space, including rare and common neurological disorders,”
said Ivana Magovčević-Liebisch Ph.D., J.D., President and Chief
Executive Officer of Vigil. “Samantha’s insights and guidance will
be particularly valuable as we continue to advance the clinical
development of VGL101 in ALSP and prepare to move our small
molecule TREM2 agonist for the treatment of Alzheimer’s disease
into the clinic this year.”
“I am thrilled to join the Vigil team at an exciting time in
their growth and evolution, and I look forward to partnering with
the leadership team and rest of the board to support their
development of treatments for both rare and common
neurodegenerative diseases through restoring the vigilance of
microglia,” said Dr. Budd Haeberlein.
Dr. Budd Haeberlein brings more than 20 years of
biopharmaceutical industry experience across research,
translational medicine, and clinical development with a focus on
CNS indications. She most recently served as Senior Vice President
and Head of Neurodegeneration Development at Biogen, where she was
responsible for the late-stage development of the company’s
Alzheimer’s, dementia and movement disorder programs. Prior to
that, Dr. Budd Haeberlein held roles of increasing responsibility
across Research and Development in the US, Canada, and Sweden with
AstraZeneca. Dr. Budd Haeberlein has led clinical programs through
early and late clinical stages, across multiple modalities and
indications, and in doing so, has shown her passion for advancing
research on biomarkers, patient selection, diagnostics, and
ultimately therapeutics for progressive neurological disorders. Dr.
Budd Haeberlein held a leadership role in the development of
ADUHELM® and LEQEMBI. For her leadership, she has been awarded the
2017 Fierce Women in Biotech Award, and in 2019 an honorary
Doctorate from the University of Dundee.
Prior to joining the biopharmaceutical industry, she was an
instructor at Harvard Medical School and did research at The
Burnham Institute. Dr. Budd Haeberlein holds a Ph.D. and B.Sc. in
Biochemistry from the University of Dundee. She is a board member
of The Boston Home, a national model for the care of adults with
advanced progressive neurological disorders.
About Vigil Neuroscience
Vigil Neuroscience is a clinical-stage biotechnology company
focused on developing treatments for both rare and common
neurodegenerative diseases by restoring the vigilance of microglia,
the sentinel immune cells of the brain. We are utilizing the tools
of modern neuroscience drug development across multiple therapeutic
modalities in our efforts to develop precision-based therapies to
improve the lives of patients and their families. VGL101, our lead
candidate, is a fully human monoclonal antibody agonist targeting
human triggering receptor expressed on myeloid cells 2 (TREM2) and
is in a Phase 2 proof-of-concept trial in patients with adult-onset
leukoencephalopathy with axonal spheroids and pigmented glia
(ALSP), a rare and fatal neurodegenerative disease. We are also
conducting IND-enabling studies with a novel small molecule TREM2
agonist program to treat common neurodegenerative diseases
associated with microglial dysfunction, with an initial focus on
Alzheimer’s disease (AD) in genetically defined subpopulations.
Forward-Looking Statements This press release
includes certain disclosures that contain “forward-looking
statements” that are made pursuant to the safe harbor provisions of
the federal securities laws, including, without limitation, express
or implied statements regarding Vigil’s strategy, business plans
and focus; the progress and timing of the preclinical and clinical
development of Vigil’s programs and other pipeline candidates; and
the anticipated contribution of the members of our board of
directors, specifically Dr. Budd Haeberlein, and our executives to
our operations and progress.
Any forward-looking statements are based on Vigil’s current
expectations and are subject to inherent uncertainties, risks and
assumptions that are difficult to predict. Factors that could cause
actual results to differ include, but are not limited to, risks and
uncertainties related to uncertainties inherent in the
identification and development of product candidates, including the
conduct of research activities and the initiation and completion of
preclinical studies and clinical trials; uncertainties as to the
availability and timing of results and data from preclinical and
clinical studies; the timing of the Company’s ability to submit and
obtain regulatory clearance for investigational new drug
applications and initiate additional clinical trials; whether
results from preclinical studies will be predictive of the results
of later preclinical studies and clinical trials; the Company’s
ability to initiate and complete its current and expected clinical
trials and its ability to work with the FDA to successfully remove
the partial clinical hold; whether Vigil’s cash resources will be
sufficient to fund its foreseeable and unforeseeable operating
expenses and capital expenditure requirements; uncertainties
associated with the impact of the COVID-19 pandemic on its business
and operations; as well as the risks and uncertainties identified
in the Company’s filings with the Securities and Exchange
Commission (SEC), including Vigil’s Annual Report on Form 10-K for
the year ended December 31, 2022 and in any subsequent filings it
may make with the SEC. Forward-looking statements contained in this
announcement are made as of this date, and Vigil undertakes no duty
to update such information except as required under applicable law.
Readers should not rely upon the information on this page as
current or accurate after its publication date.
Investor Contact:Stern Investor
RelationsSternIR-Vigil@sternir.com
Media Contact:Megan McGrath MacDougall
Advisorsmmcgrath@macdougall.bio
###
Vigil Neuroscience (NASDAQ:VIGL)
Historical Stock Chart
From Apr 2024 to May 2024
Vigil Neuroscience (NASDAQ:VIGL)
Historical Stock Chart
From May 2023 to May 2024